Multicentre validation of an immune-inflammation-based nomogram to predict survival in western resectable gastroesophageal adenocarcinoma: The NOMOGAST by Salati, M et al.
abstracts Annals of Oncologyboth questionnaires and verbal interviews. Incident cases were identified by linkage with
routinely collected hospital inpatient and cancer registry data for England, Scotland and
Wales. Primary clinical outcomes were GORD without oesophagitis, GORD with
oesophagitis (reflux oesophagitis), Barrett’s oesophagus and oesophageal adenocarci-
noma. The effects of heavy manual activity on disease risk were estimated using Cox
proportional hazard regression adjusted for multiple risk factors and stratified by socio-
economic status.
Results: Between 2006 and 2010, 502 men and 524 women were enrolled. Main
analyses were limited to the working population with a full set of variables of interest
(n¼266, 453). Compared to jobs with low levels of heavy manual activity, high-level
jobs had increased hazard ratios (HRs) for GORD (1.20, 95% CI 1.11-1.30), reflux
oesophagitis (1.17, 95% CI 1.04-1.31) and Barrett’s oesophagus (1.13, 95% CI 0.98-
1.32), but not oesophageal adenocarcinoma (0.91 95% CI 0.54-1.56).
Conclusion: High levels of occupational heavy manual activity could be used as a new
risk factor for GORD and reflux oesophagitis, the precursor diseases of oeosphageal
adenocarcinoma.
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Background: Gastric cancer (GC) is the third cause of death from cancer in the world
and is the first cause of death in men and the fourth in women for Colombia. The
bacteria Helicobacter pylori (H. pylori) is a class I human carcinogen for GC. The
presence of the gene associated with cytotoxin A (cagA) and the s1 and m1 alleles in
the vacuolizing cytotoxin A (vacA) gene, are associated with the development of
neoplastic lesions.
Methods: We molecularly evaluated the virulence profile of H. pylori strains present
in 93 patients with GC and 377 patients with premalignant lesions from Ibagué-
Colombia. The DNA from the antral biopsies was extracted using the DNeasy Blood &
Tissue Kit of QIAGEN. The bacterium was identified by PCR amplification of a fragment
of the 16s rDNA gene and the genotypes were identified by amplification of frag-
ments of the cagA, cagE genes and the signal (s1/s2 alleles) and medium (m1/m2
alleles) regions of vacA gene. The PCRs were performed separately in a Biorad Dual-
Touch 1000 thermocycler. The amplification products were visualized by electropho-
resis in agarose gels.
Results: The prevalence of H. pylori infection was 44% and 23 genotypes of strains
were identified. We observed a decrease in the number of genotypes and an increase
in the frequency of the cagA/cagE/vacAs1m1 genotype according to the degree of
gastric lesion increases. 41,1% (131/318) of patients with chronic non-atrophic gastritis
were infected with H. pylori; we found the highest number of genotypes in this group
of patients. 35% of those infected had the vacAs2m2 non-pathogenic genotype, 30%
had the cagA/cagE/vacAs1m1 pathogenic genotype and the remaining patients had
intermediate genotypes with one or two oncogenes or alleles associated with path-
ogenicity. 42,3% (25/59) of patients with preneoplastic pathologies were positive for
infection, 8% had the non-pathogenic genotype and 64% had the pathogenic genotype.
In patients with GC, 52,3% (49/93) were positive for the infection, 57% had a patho-
genic genotype and only one patient had the non-pathogenic genotype.
Conclusion: We identified the cagA/cagE/vacAs1m1 pathogenic genotype and the
vacAs2m2 non-pathogenic genotype reported in the literature and 21 intermediate
genotypic variants. These genotypes could explain the variations in the clinic response
to infection. Our results support the hypothesis of positive selection towards the
genotypes considered to be pathogenic as the severity of gastric injury increases.
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Background: Despite standard multimodality treatment, > 50% of operable gastro-
esophageal adenocarcinoma (GEA) relapse following curative-intent surgery in theWest.
Although treatment decision relies on established clinicopathologic features, they are
flawed by a limited predictive value and inability to capture interpatient heterogeneity.
We aimed at externally validating our previously-describednomogram (Salati et al. ESMO
2019) to enable a more accurate estimate of individualized risk in resected GEA.
Methods: Electronic medical records of patients undergoing curative-intent surgery
for c/uT2-T4 and/or node-positive gastric and gastroesophageal junction adenocar-
cinoma were retrieved and variables deemed of potential interest were collected. The
Modena Cancer Centre cohort served as the training cohort (TC), while the joint
cohort of Cremona Cancer Centre and Forlì Cancer Centre served as the validation
cohort (VC). Cox proportional hazards in univariate and multivariate regression were
used to assess the effects of the prognostic factors on OS. A graphical nomogram,
derived from the multivariate Cox regression model, was constructed using the
package Regression Modeling Strategies (ver. 5.0-1) in R software. The performance of
the prognostic model was evaluated and external validation performed.
Results: The TC and VC consisted of 112 and 319 patients, respectively. The following
covariates retained independent prognostic value in the TC and were used for the con-
struction of a nomogram estimating 3-year and 5-year OS: ECOG PS >0 (p 0 (vs 61%;
p¼0.24), 39% angioinvasion (vs 50%; p¼0.05), and 67% were node-positive (vs 80%;
p¼0.08); junctional cancers account for 16% (vs 12%; p¼0.15) of the overall population
and 42% (vs 48%; p¼0.25) of patients received adjuvant chemotherapy.The discriminatory
ability of the prognosticmodelwas evaluatedwith the c-Harrell index (0.78 and 0.76, in the
VC and TC, respectively). Then, a 3-tier scoring system was developed through a linear
predictor grouped by25and 75percentiles,which strengthened the gooddiscrimination of
the model (p< 0.001). A calibration plot demonstrated concordance between the pre-
dicted survival and actual survival both in the TC and VC. Finally, a decision curve analysis
was plotted that depicts the clinical utility (net benefit) of the nomogram.
Conclusion: We externally validated a prognostic nomogram to predict 3-year and 5-
year OS in a joint independent cohort of resectable GEA. This tool incorporates
readily-available and inexpensive patient and disease characteristics, as well as im-
mune-inflammatory determinants. It has been shown to be accurate (well-calibrated
with good discriminative ability), generalizable and clinically effective. Although a
prospective validation in a larger patient population is warranted, the NOMOGAST
could represent a useful tool to be implemented in the clinic to assist decision-making
and clinical trial design.
Legal entity responsible for the study: The author.
Funding: Has not received any funding.
Disclosure: The presenting author has declared no conflicts of interest.
https://doi.org/10.1016/j.annonc.2020.04.027SO-13 Can we screen for pancreatic cancer? Identifying a sub-population
of patients at high risk of subsequent diagnosis using machine
learning techniques applied to primary care data
A. Malhotra1, B. Rachet1, A. Bonaventure2, S. Pereira3, L. Woods1
1London School of Hygiene and Tropical Medicine, London, United Kingdom; 2CRESS,
University of Paris, Paris, France; 3UCL Institute for Liver and Digestive Health, London,
United Kingdom
Background: Ninety-four percent of pancreatic cancer patients die within 5 years of
their diagnosis. Most patients experience no obvious symptoms until the tumour is
well advanced. It is now possible, via a blood test, to detect pancreatic cancer before
symptoms of late-stage disease are evident. However, in order to be cost-effective,
this test should only be applied to a limited group of individuals.
Methods: We conducted a national, population-based, case-control study to deter-
mine whether it is possible to identify a sub-population of patients at high risk of
developing pancreatic cancer. Our hypothesis was that patients with early malignancy
share similar profiles of early, diffuse, warning signs which might be detectable
through the application of machine learning approaches.We used the Clinical PracticeS221
